Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.

BACKGROUND: Anti-mitotic compounds (microtubule de-stabilizers) such as vincristine and vinblastine have been shown clinically successful in treating various cancers. However, development of drug-resistance cells limits their efficacies in clinical situations. Therefore, experiments were performed t...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Chun Hei Antonio Cheung, Su-Ying Wu, Tian-Ren Lee, Chi-Yen Chang, Jian-Sung Wu, Hsing-Pang Hsieh, Jang-Yang Chang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2010-01-01
Online Access:	http://europepmc.org/articles/PMC2933234?pdf=render